Status:

RECRUITING

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)

Lead Sponsor:

University of Maryland, Baltimore

Conditions:

Pain

Virtual Reality

Eligibility:

All Genders

18-88 years

Phase:

NA

Brief Summary

This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for ...

Detailed Description

Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and acute) pain. An approach to pain management utilizing VR presents opportunities for reducing pain and suffer...

Eligibility Criteria

Inclusion

  • Age (18-88 years)
  • English speaker (written and spoken)
  • Temporal Mandibular Disorder (TMD) for at least 3 months
  • TMD Grade Chronic Pain Scale (GCPS) ≥ 0

Exclusion

  • Present or past degenerative neuromuscular disease
  • Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years
  • Cervical pain (e.g. stenosis, radiculopathy)
  • Any personal (or family first degree) history of mania, schizophrenia, or other psychoses
  • Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.
  • Use of Antipsychotics (e.g., Risperdal, Ability and clozaril)Lifetime alcohol/drug dependence or alcohol/drug abuse in past 3 months
  • Pregnancy or breast feeding
  • Color-blindness
  • Impaired or uncorrected hearing
  • Non-dominant hand
  • Any facial trauma that has occurred in the last 6 weeks
  • History of a severe facial trauma in the last 2-3 months
  • Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)
  • Known history of severe motion sickness
  • Non-removable head cover, artificial hair, certain types of braids or dreadlocks
  • History of fainting
  • History of angioedema
  • Failed drug test (testing for opiates, cocaine, methamphetamines, and amphetamines)

Key Trial Info

Start Date :

April 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2026

Estimated Enrollment :

78 Patients enrolled

Trial Details

Trial ID

NCT06214923

Start Date

April 9 2024

End Date

November 30 2026

Last Update

June 29 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Luana Colloca

Baltimore, Maryland, United States, 21201-1512

2

University of Maryland

Baltimore, Maryland, United States, 21201-1512